World Journal of Nuclear Medicine

Access statistics : Table of Contents
2012| September-December | Volume 11 | Issue 3
Online since November 10, 2012

Archives

Previous Issue

Next Issue

Most popular articles

Most cited articles

Hide all abstracts Show selected abstracts Export selected to

Viewed

PDF

Cited

EDITORIALS

When was the Last Time You did Something for the First Time?
Ajit Kumar Padhy
September-December 2012, 11(3):99-100
DOI:10.4103/1450-1147.103404 PMID:23372444

[FULL TEXT] [PDF] [Mobile Full text] [EPub] [PubMed]

2,184

10,928

ABSTRACTS

ICRT-Abstracts of Poster Presentations

September-December 2012, 11(3):160-200

[FULL TEXT] [PDF] [Mobile Full text] [EPub]

4,619

352

ICRT-Speakers' Abstracts

September-December 2012, 11(3):121-153

[FULL TEXT] [PDF] [Mobile Full text] [EPub]

3,565

265

EDITORIALS

Nuclear Medicine in Finland
Kalevi Kairemo
September-December 2012, 11(3):101-102
DOI:10.4103/1450-1147.103406 PMID:23372445

[FULL TEXT] [PDF] [Mobile Full text] [EPub] [PubMed]

1,876

1,877

Global WARMTH for Patients with Cancer
J Harvey Turner
September-December 2012, 11(3):103-104
DOI:10.4103/1450-1147.103407 PMID:23372446

[FULL TEXT] [PDF] [Mobile Full text] [EPub] [PubMed]

1,609

1,767

ORIGINAL ARTICLES

Standard Operating Procedure for In-house Preparation of ¹³¹ I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
Matthew D Pickford, J Harvey Turner
September-December 2012, 11(3):105-109
DOI:10.4103/1450-1147.103408 PMID:23372447

A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of ¹³¹ I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.

[ABSTRACT] [FULL TEXT] [PDF] [Mobile Full text] [EPub] [CITATIONS] [PubMed]

2,859

515

Standard Operating Procedure for Prospective Individualised Dosimetry for ^[131] I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
Phillipe J Calais, J Harvey Turner
September-December 2012, 11(3):110-116
DOI:10.4103/1450-1147.103409 PMID:23372448

Radioimmunotherapy (RIT) is an attractive therapy for non-Hodgkin's lymphoma (NHL) as it allows targeted tumor irradiation which provides a cytotoxic effect significantly greater than that of the immune-mediated effects of a non-radioactive, or 'cold', antibody alone. Anti-CD20 antibodies such as rituximab are ideal for RIT, as not only is it easily iodinated, but the CD20 antigen is found on more than 95% of B-cell NHL. A standard operating procedure (SOP) has been formulated for personalized prospective dosimetry for safe, effective outpatient ¹³¹ I-rituximab RIT of NHL. Over five years, experience of treatment of outpatients with ¹³¹ I-rituximab was analyzed with respect to critical organ radiation dose in patients and radiation exposure of their carers. This radiation safety methodology has been refined; and offers the potential for safe, practical application to outpatient ¹³¹ I-rituximab RIT of lymphoma in general and in developing countries in particular. Given endorsement and sanction of this SOP by local regulatory authorities the personalized dosimetry paradigm will facilitate incorporation of RIT into the routine clinical practice of therapeutic nuclear oncology worldwide.

[ABSTRACT] [FULL TEXT] [PDF] [Mobile Full text] [EPub] [CITATIONS] [PubMed]

2,493

512

ABSTRACTS

ICRT-Abstracts of Oral Presentations

September-December 2012, 11(3):154-159

[FULL TEXT] [PDF] [Mobile Full text] [EPub]

2,784

200

Warmth 7^th International Conference on Radiopharmaceutical Therapy (Icrt 2012) Levi, Finland

September-December 2012, 11(3):117-117

[FULL TEXT] [PDF] [Mobile Full text] [EPub]

1,153

185

Pre-conference Symposium on Nuclear Cardiology

September-December 2012, 11(3):118-121

[FULL TEXT] [PDF] [Mobile Full text] [EPub]

1,057

150